AR018185A1 - Compuestos triciclicos substituidos utiles como inhibidores de la liberacion de acidos grasos mediada por spla2 en mamiferos y uso de dichos compuestos enla fabricacion de composiciones para aliviar los efectos patologicos de enfermedades relacionadas con spla2 - Google Patents
Compuestos triciclicos substituidos utiles como inhibidores de la liberacion de acidos grasos mediada por spla2 en mamiferos y uso de dichos compuestos enla fabricacion de composiciones para aliviar los efectos patologicos de enfermedades relacionadas con spla2Info
- Publication number
- AR018185A1 AR018185A1 ARP990101769A ARP990101769A AR018185A1 AR 018185 A1 AR018185 A1 AR 018185A1 AR P990101769 A ARP990101769 A AR P990101769A AR P990101769 A ARP990101769 A AR P990101769A AR 018185 A1 AR018185 A1 AR 018185A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- nitrogen
- spla2
- substituted
- hydrogen
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 235000014113 dietary fatty acids Nutrition 0.000 title abstract 2
- 229930195729 fatty acid Natural products 0.000 title abstract 2
- 239000000194 fatty acid Substances 0.000 title abstract 2
- 150000004665 fatty acids Chemical class 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000001575 pathological effect Effects 0.000 title 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 11
- 229910052757 nitrogen Inorganic materials 0.000 abstract 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 5
- 229910052799 carbon Inorganic materials 0.000 abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 230000002452 interceptive effect Effects 0.000 abstract 5
- 125000001424 substituent group Chemical group 0.000 abstract 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 3
- 239000002253 acid Substances 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 239000011593 sulfur Substances 0.000 abstract 3
- 125000004429 atom Chemical group 0.000 abstract 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 239000001301 oxygen Substances 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 102000005473 Secretory Phospholipases A2 Human genes 0.000 abstract 1
- 108010031873 Secretory Phospholipases A2 Proteins 0.000 abstract 1
- 206010040070 Septic Shock Diseases 0.000 abstract 1
- XOCUXOWLYLLJLV-UHFFFAOYSA-N [O].[S] Chemical group [O].[S] XOCUXOWLYLLJLV-UHFFFAOYSA-N 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 230000036303 septic shock Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/58—[b]- or [c]-condensed
- C07D209/70—[b]- or [c]-condensed containing carbocyclic rings other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pyridine Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6216598A | 1998-04-17 | 1998-04-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR018185A1 true AR018185A1 (es) | 2001-10-31 |
Family
ID=22040624
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990101769A AR018185A1 (es) | 1998-04-17 | 1999-04-16 | Compuestos triciclicos substituidos utiles como inhibidores de la liberacion de acidos grasos mediada por spla2 en mamiferos y uso de dichos compuestos enla fabricacion de composiciones para aliviar los efectos patologicos de enfermedades relacionadas con spla2 |
Country Status (27)
| Country | Link |
|---|---|
| EP (2) | EP1156050B1 (enExample) |
| JP (1) | JP4435325B2 (enExample) |
| KR (1) | KR19990083234A (enExample) |
| CN (1) | CN1235968A (enExample) |
| AR (1) | AR018185A1 (enExample) |
| AT (2) | ATE254128T1 (enExample) |
| AU (1) | AU757454B2 (enExample) |
| BR (1) | BR9901275A (enExample) |
| CA (1) | CA2269256A1 (enExample) |
| CO (1) | CO5080728A1 (enExample) |
| CZ (1) | CZ137199A3 (enExample) |
| DE (2) | DE69912670T2 (enExample) |
| EA (1) | EA003129B1 (enExample) |
| ES (2) | ES2210979T3 (enExample) |
| HU (1) | HUP9901219A1 (enExample) |
| ID (1) | ID23219A (enExample) |
| IL (1) | IL129484A0 (enExample) |
| NO (1) | NO991823L (enExample) |
| NZ (1) | NZ335252A (enExample) |
| PE (1) | PE20000472A1 (enExample) |
| PL (1) | PL332564A1 (enExample) |
| SG (1) | SG106035A1 (enExample) |
| SV (1) | SV1999000052A (enExample) |
| TR (1) | TR199900842A2 (enExample) |
| TW (1) | TW555760B (enExample) |
| YU (1) | YU19099A (enExample) |
| ZA (1) | ZA992773B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2301586A1 (en) * | 1997-08-28 | 1999-03-04 | William Louis Macias | Method for treatment of non-rheumatoid arthritis |
| AU2001244635A1 (en) * | 2000-03-30 | 2001-10-15 | Yamanouchi Pharmaceutical Co..Ltd. | Hydrazide derivatives |
| EP1303262A2 (en) * | 2000-07-14 | 2003-04-23 | Eli Lilly And Company | Use of a spla2 inhibitor for the treatment of sepsis |
| AU2002239264A1 (en) * | 2000-12-18 | 2002-07-01 | Eli Lilly And Company | Tetracyclic derivatives as spla2 inhibitors |
| US6933313B2 (en) | 2001-03-28 | 2005-08-23 | Eli Lilly And Company | Substituted carbazoles as inhibitors of sPLA2 |
| JP2005527466A (ja) * | 2001-08-09 | 2005-09-15 | イーライ・リリー・アンド・カンパニー | ｓＰＬＡ２インヒビターとしてのシクロヘプトＢインドール誘導体 |
| JP2005527464A (ja) * | 2001-08-09 | 2005-09-15 | イーライ・リリー・アンド・カンパニー | ｓＰＬＡ２インヒビターとしてのシクロヘプタＢインドール誘導体 |
| US6992100B2 (en) | 2001-12-06 | 2006-01-31 | Eli Lilly And Company | sPLA2 inhibitors |
| MX2007005199A (es) | 2004-11-01 | 2007-05-11 | Wyeth Corp | Indolizinas sustituidas y derivados como agentes del sistema nervioso central. |
| BRPI0907122B8 (pt) | 2008-01-11 | 2021-05-25 | Albany Molecular Res Inc | compostos de piridoindóis (1-azinona) substituídos, composição farmacêutica compreendendo os referidos compostos, e usos dos mesmos |
| US9073925B2 (en) | 2009-07-01 | 2015-07-07 | Albany Molecular Research, Inc. | Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof |
| WO2012088124A2 (en) | 2010-12-21 | 2012-06-28 | Albany Molecular Research, Inc. | Tetrahydro-azacarboline mch-1 antagonists, methods of making, and uses thereof |
| JP5964945B2 (ja) * | 2011-04-14 | 2016-08-03 | アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ | ７−（ヘテロアリ−ル−アミノ）−６，７，８，９−テトラヒドロピリド［１，２−ａ］インド−ル酢酸誘導体及びプロスタグランジンＤ２受容体調節剤としてのそれらの使用 |
| SG11201405328SA (en) | 2012-03-16 | 2014-11-27 | Vitae Pharmaceuticals Inc | Liver x receptor modulators |
| SMT201700009T1 (it) | 2012-03-16 | 2017-03-08 | Vitae Pharmaceuticals Inc | Modulatori del recettore x del fegato |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3979391A (en) * | 1972-11-22 | 1976-09-07 | Sterling Drug Inc. | 1,2,3,4-Tetrahydrocarbazoles |
| PT95692A (pt) * | 1989-10-27 | 1991-09-13 | American Home Prod | Processo para a preparacao de derivados de acidos indole-,indeno-,piranoindole- e tetra-hidrocarbazole-alcanoicos, ou quais sao uteis como inibidores de pla2 e da lipoxigenase |
| IL109309A (en) * | 1993-04-16 | 2000-06-29 | Lilly Co Eli | 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them |
| IL109311A0 (en) * | 1993-04-16 | 1994-07-31 | Lilly Co Eli | 1H-indole-3-acetamide sPla2 inhibitors |
| BR9508298A (pt) * | 1994-07-21 | 1998-11-03 | Shionogi & Co | Inibidores de indolizina de spla2 |
| US6160175A (en) * | 1995-12-13 | 2000-12-12 | Eli Lilly And Company | Naphthyl acetamides as sPLA2 inhibitors |
| KR20000049210A (ko) * | 1996-10-30 | 2000-07-25 | 피터 지. 스트링거 | 치환된 트리시클릭류 |
| CA2304482A1 (en) * | 1997-09-26 | 1999-04-08 | Eli Lilly And Company | Method for the treatment of cystic fibrosis |
| CA2310250A1 (en) * | 1997-11-14 | 1999-05-27 | August Masaru Watanabe | Treatment for alzheimer's disease |
-
1999
- 1999-04-15 IL IL12948499A patent/IL129484A0/xx unknown
- 1999-04-15 ID IDP990342D patent/ID23219A/id unknown
- 1999-04-16 PE PE1999000321A patent/PE20000472A1/es not_active Application Discontinuation
- 1999-04-16 EP EP01203116A patent/EP1156050B1/en not_active Expired - Lifetime
- 1999-04-16 YU YU19099A patent/YU19099A/sh unknown
- 1999-04-16 ZA ZA9902773A patent/ZA992773B/xx unknown
- 1999-04-16 CO CO99022891A patent/CO5080728A1/es unknown
- 1999-04-16 ES ES99302969T patent/ES2210979T3/es not_active Expired - Lifetime
- 1999-04-16 SG SG9901844A patent/SG106035A1/en unknown
- 1999-04-16 NZ NZ335252A patent/NZ335252A/xx unknown
- 1999-04-16 CA CA002269256A patent/CA2269256A1/en not_active Abandoned
- 1999-04-16 AU AU23818/99A patent/AU757454B2/en not_active Ceased
- 1999-04-16 KR KR1019990013439A patent/KR19990083234A/ko not_active Withdrawn
- 1999-04-16 EP EP99302969A patent/EP0950661B1/en not_active Expired - Lifetime
- 1999-04-16 CN CN99108097A patent/CN1235968A/zh active Pending
- 1999-04-16 PL PL99332564A patent/PL332564A1/xx not_active Application Discontinuation
- 1999-04-16 AT AT99302969T patent/ATE254128T1/de not_active IP Right Cessation
- 1999-04-16 ES ES01203116T patent/ES2213668T3/es not_active Expired - Lifetime
- 1999-04-16 CZ CZ991371A patent/CZ137199A3/cs unknown
- 1999-04-16 EA EA199900304A patent/EA003129B1/ru not_active IP Right Cessation
- 1999-04-16 DE DE69912670T patent/DE69912670T2/de not_active Expired - Fee Related
- 1999-04-16 NO NO991823A patent/NO991823L/no not_active Application Discontinuation
- 1999-04-16 TW TW088106131A patent/TW555760B/zh not_active IP Right Cessation
- 1999-04-16 BR BR9901275-8A patent/BR9901275A/pt not_active IP Right Cessation
- 1999-04-16 SV SV1999000052A patent/SV1999000052A/es not_active Application Discontinuation
- 1999-04-16 HU HU9901219A patent/HUP9901219A1/hu unknown
- 1999-04-16 AR ARP990101769A patent/AR018185A1/es not_active Application Discontinuation
- 1999-04-16 AT AT01203116T patent/ATE259818T1/de not_active IP Right Cessation
- 1999-04-16 DE DE69914951T patent/DE69914951T2/de not_active Expired - Fee Related
- 1999-04-16 TR TR1999/00842A patent/TR199900842A2/xx unknown
- 1999-04-16 JP JP10965699A patent/JP4435325B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR018593A1 (es) | COMPUESTOS TRICICLICOS SUSTITUIDOS, FORMULACIoN FARMACÉUTICA QUE LO COMPRENDE, USO DE DICHO COMPUESTO PARA FABRICAR UN MEDICAMENTO uTIL PARA INHIBIR SELECTIVAMENTE SPLA2 Y ALIVIAR EFECTOS PATOLoGICOS DE ENFERMEDADES RELACIONADAS | |
| CO4920250A1 (es) | Compuestos heterociclicos utiles en la inhibicion de la spla2 | |
| ECSP056222A (es) | Derivados de indazolil(indolil)maleimida sustituidoscomo inhibidores de cinasa | |
| EA200600358A1 (ru) | Фенил- или пиридиламидные соединения в качестве антагонистов простагландина е2 | |
| ME00768B (me) | Derivati supstituisanih benzol sulfonamida kao pro-lekovi cox-2 inhibitora | |
| BR0314586A (pt) | Composições de tratamento para furos de sondagem com fase de óleo de baixa toxicidade | |
| CO4970702A1 (es) | Quinolonas antimicrobianas, sus composiciones y sus usos | |
| UY24908A1 (es) | Derivados del ácido hexanoico | |
| ES2171189T3 (es) | Derivados de fenilo tri-sustituidos utiles como inhibidores de pde iv. | |
| FR2361889A1 (fr) | Nouveaux derives de 1-(benzazolyalcoyl)piperidine | |
| BR9915895A (pt) | Composto, uso do mesmo, processo para prepará-lo, método para o tratamento de um mamìfero, incluindo o homem, de condições resultantes de nìveis de circulação elevados de apob-100, e, composição farmacêutica | |
| GB930136A (en) | Improvements in or relating to lubricating compositions | |
| CO5080728A1 (es) | Compuestos triciclicos sustituidos | |
| ES2159347T3 (es) | Naftil-acetamidas como inhibidores de spla2. | |
| PE20030763A1 (es) | Inhibidores de la integrasa del vih | |
| CO5040004A1 (es) | 2-4-diamino-1,3,5-triazinas, su preparacion y empleo como herbicidas y fitorreguladores | |
| BG60338B2 (en) | Thienothiazines | |
| ES8704503A1 (es) | Procedimiento para preparar sales de ciclimonio | |
| ES2171306T3 (es) | Compuesto bajo la forma de isomero geometrico puro o de una mezcla de estos isomeros. | |
| GB9007338D0 (en) | Chemical compounds | |
| ES2174034T3 (es) | Naftilglioxamidas como inhibidores de spla2 | |
| PE20001052A1 (es) | Inhibidores de hiv proteasa | |
| CL2024003427A1 (es) | Derivados de pirrolidinona como inhibidores de quinasa inductora de nf-kb. | |
| AR246094A1 (es) | Composicion de aceite lubricante sin cenizas para motores diesel y un concentrado para preparar la misma. | |
| ES468940A1 (es) | Procedimiento para la produccion de oximas o-alquiladas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |